What Does the FAERS Data Reveal About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Legal Recourse

If you or someone you know has developed uncontrollable muscle movements after taking Reglan, you may be concerned about the connection to tardive dyskinesia. Decades of medical literature and adverse event reporting have established a clear link between prolonged metoclopramide use and this movement disorder. This page reviews the documented safety context from the FDA Adverse Event Reporting System (FAERS) to provide a factual overview of the known risks.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis, but its association with tardive dyskinesia (TD) is a serious and well-documented risk. TD is a movement disorder characterized by potentially irreversible involuntary movements, often involving the face, tongue, trunk, or extremities. The clinical presentation of TD can include repetitive, jerking, or writhing motions that may be disfiguring and interfere with daily function. Diagnosis is typically based on clinical observation of these abnormal movements after exposure to a dopamine-blocking agent like metoclopramide, with no definitive laboratory test available. Reglan's pharmacology involves dopamine receptor antagonism in the central nervous system, which is the mechanistic pathway linked to TD. Chronic blockade of dopamine D2 receptors in the basal ganglia is believed to lead to receptor upregulation and supersensitivity, contributing to the development of involuntary movements. The risk of TD increases with longer treatment duration and higher cumulative doses, as highlighted in the FDA-approved boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning explicitly states that metoclopramide can cause TD, a potentially irreversible serious movement disorder, and that risk increases with duration of treatment and total cumulative dosage.

Legal Considerations for Illinois Patients

For affected patients in Illinois, attorney-related considerations are important. The statute of limitations for personal injury claims in Illinois is generally two years from the date the injury was discovered or should have been discovered. For TD, the timeline between exposure and documented harm can be variable. TD may develop after months or years of Reglan use, and symptoms can emerge even after the drug is discontinued. This latency period complicates the determination of when the statute of limitations begins. Patients who develop TD after prolonged Reglan use may need to establish when they first noticed symptoms or when a diagnosis was made. Legal claims may focus on failure to warn, inadequate monitoring, or prolonged prescribing beyond recommended durations. The boxed warning and prescribing information provide clear evidence that the manufacturer warned about TD risk, but individual cases may involve allegations that warnings were not effectively communicated to patients or that prescribers deviated from standard care. The timeline between exposure and documented harm is a key factor in legal cases. Evidence shows that Reglan is indicated only for short-term use, with a maximum of 12 weeks for gastroesophageal reflux and similar limitations for diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, some patients may be prescribed Reglan for months or years, increasing cumulative exposure and TD risk. The boxed warning emphasizes that risk increases with duration and total dosage, so longer exposure strengthens the causal link. For patients in Illinois, documenting the duration of Reglan use, the dosage, and the onset of TD symptoms is essential for legal claims. Medical records, prescription histories, and expert testimony can help establish the timeline.

Risk Context and FDA Warnings

Reglan is contraindicated in patients with a history of TD, and the medication should be used for the shortest duration necessary, with periodic reassessment of continued need. For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks, and for diabetic gastroparesis, treatment beyond 12 weeks should be avoided unless longer use is unavoidable, in which case routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The adequacy of warnings regarding Reglan and TD is a critical risk anchor. The boxed warning is prominently placed in the prescribing information, but despite this, many patients may not receive adequate counseling about the risk before starting treatment. The warning advises immediate discontinuation of Reglan if signs or symptoms of TD develop, but the condition can be irreversible even after stopping the drug. Additionally, the medication may suppress or partially suppress TD signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This raises concerns about whether prescribers and patients are fully informed of the risks, especially given that Reglan is sometimes used off-label or for longer periods than recommended.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Illinois?

In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For tardive dyskinesia caused by Reglan, this means the clock starts when you first noticed symptoms or received a diagnosis. Because TD can develop months or years after starting Reglan, it is crucial to consult an attorney promptly to preserve your claim.

How does the FDA boxed warning for Reglan impact legal cases?

The FDA boxed warning for Reglan explicitly states that metoclopramide can cause tardive dyskinesia, a potentially irreversible movement disorder, and that risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning serves as strong evidence that the manufacturer warned about the risk, but legal claims may still focus on whether the warning was effectively communicated to patients or whether prescribers deviated from standard care by prescribing Reglan for longer than recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.